日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model

利用QSP模型鉴定T细胞衔接器治疗葡萄膜黑色素瘤的生物标志物

Anbari, Samira; Wang, Hanwen; Arulraj, Theinmozhi; Nickaeen, Masoud; Pilvankar, Minu; Wang, Jun; Hansel, Steven; Popel, Aleksander S

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics

生物治疗药物产业化趋势:89种抗体生物治疗药物产品特性调查

Martin, Kyle P; Grimaldi, Christine; Grempler, Rolf; Hansel, Steven; Kumar, Sandeep

Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager

利用定量系统药理学模型优化抗PD-L1检查点抑制剂和T细胞衔接器的联合疗法

Anbari, Samira; Wang, Hanwen; Zhang, Yu; Wang, Jun; Pilvankar, Minu; Nickaeen, Masoud; Hansel, Steven; Popel, Aleksander S

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

使用大鼠抗小鼠 IL-36R 单克隆抗体和 RNA 表达数据 (FANTOM5) 对抗 IL-36R 单克隆抗体 MAB92 的人体药代动力学进行基于模型的预测的回顾性分析

Ahlberg Jennifer, Giragossian Craig, Li Hua, Myzithras Maria, Raymond Ernie, Caviness Gary, Grimaldi Christine, Brown Su-Ellen, Perez Rocio, Yang Danlin, Kroe-Barrett Rachel, Joseph David, Pamulapati Chandrasena, Coble Kelly, Ruus Peter, Woska Joseph R, Ganesan Rajkumar, Hansel Steven, Mbow M Lamine